New combo aims to clear hepatitis b virus

NCT ID NCT05970289

Ongoing Disease control Sponsor: Brii Biosciences Limited Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 34 times

Summary

This phase 2 study tests whether adding a new drug called BRII-835 to standard pegylated interferon alpha can help people with chronic hepatitis B lose a key virus marker (HBsAg) from their blood. About 86 adults aged 18-60 who have been on antiviral therapy for at least 6 months will receive either the combination or interferon alone. The goal is to see if the combo is safe and more effective at clearing the virus.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Investigative Site 61001

Kingswood, New South Wales, 2747, Australia
Investigative Site 61002

Birtinya, Queensland, 4575, Australia
Investigative Site 61003

Melbourne, Victoria, 3004, Australia
Investigative Site 65001

Singapore, 169856, Singapore
Investigative Site 65002

Singapore, 529889, Singapore
Investigative Site 66003

Bangkok, 10330, Thailand
Investigative Site 66005

Khon Kaen, 40002, Thailand
Investigative Site 66006

Nonthaburi, 11000, Thailand
Investigative Site 66008

Songkhla, 90110, Thailand
Investigative Site 82001

Busan, 49241, South Korea
Investigative Site 82002

Chuncheon, Chuncheon-si, 24253, South Korea
Investigative Site 82003

Seoul, 6351, South Korea
Investigative Site 82004

Daegu, 41566, South Korea
Investigative Site 82005

Seoul, 13496, South Korea
Investigative Site 82006

Soeul, 05505, South Korea
Investigative Site 85201

Hong Kong, HONG KONG, 999077, China
Investigative Site 85202

Hong Kong, HONG KONG, 999077, China
Investigative Site 86001

Beijing, Beijing Municipality, 100000, China
Investigative Site 86001

Beijing, Beijing Municipality, 100050, China
Investigative Site 86004

Chongqing, Chongqing Municipality, 400010, China
Investigative Site 86006

Guangzhou, Guangdong, 510630, China
Investigative Site 86007

Beijing, Beijing Municipality, 100069, China
Investigative Site 86008

Changchun, Jilin, 130021, China
Investigative Site 86011

Hangzhou, Zhengjiang, 310016, China
Investigative Site 86013

Shanghai, Shanghai Municipality, 200025, China
Investigative Site 88601

Kaohsiung, Taiwan, 80756, China
Investigative Site 88602

Taipei, Taiwan, 10041, China
Investigative Site 88603

Taipei, Taiwan, 11217, China
nvestigative Site 66007

Chiang Mai, 50200, Thailand

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BRII-835 (a drug) and pegylated interferon alpha (a biologic)

What this could lead to

If successful, this combination could help more people with chronic hepatitis B clear the virus from their blood, potentially reducing the need for lifelong medication.

What could go wrong

This is an early phase 2 trial with only 86 participants, so results may not apply to everyone. The treatment may cause side effects like flu-like symptoms or serious adverse events, and it may not work for all patients.

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B VIRUS INFECTION